Attributable Hospital Cost and Antifungal Treatment of Invasive Fungal Diseases in High-Risk Hematology Patients: an Economic Modeling Approach
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Studies using patient-level data to determine the attributable cost of invasive fungal diseases (IFDs) are few. Using a case-control study with activity-based costing of patients admitted to a quaternary hospital from 2002 to 2007, we determined attributable hospitalization cost (and 12 weeks thereafter), length of stay (LOS), and costly antifungal treatment (C-AT; liposomal amphotericin B, voriconazole, posaconazole, caspofungin), expressed as defined daily doses (DDDs) per IFD episode, in patients with hematological malignancies and hematopoietic stem cell recipients. Matching criteria and median regression modeling controlled for confounding variables, including LOS prior to IFD onset. Multiple mycoses were identified in 43 matched case-control pairs ( n = 86). A separate sensitivity analysis included 22 unmatched patients. IFD status was associated with a median excess cost of AU$30,957 (95% confidence interval [CI] = AU$2,368 to AU$59,546; P = 0.034), approximating at purchasing power parity US$21,203 (95% CI = US$1,622 to US$40,784) and €15,788 (95% CI = €1,208 to €30,368), increasing to AU$80,291 (95% CI = AU$33,636 to AU$126,946; P = 0.001), i.e., US$54,993 (95% CI = US$23,038 to US$86,948) and €40,948 (95% CI = €17,154 to €64,742), with intensive care unit (ICU) requirement. Cost determinants were pharmacy costs (64%; P < 0.001) inclusive of antifungal treatment (27%; P < 0.001) and ward costs (27%; P = 0.091), with proportions persisting through 12 weeks for 25 surviving matched pairs (pharmacy, 60% [ P = 0.12]; ward, 31% [ P = 0.21]). Median LOS was not significantly increased unless unmatched patients were included (8 days, 95% CI = 1.8 to 14 days; P = 0.012). Excess C-ATs were 17 DDDs (95% CI = 15 to 19 DDDs; P < 0.001) per case patient and 19 DDDs (95% CI = 16 to 22 DDDs; P < 0.001) per ICU patient. The sensitivity analysis was confirmatory (for median cost, AU$29,441, 95% CI = AU$5,571 to AU$53,310, P = 0.016; for C-AT, 17 DDDs, 95% CI = 16 to 18 DDDs, P < 0.001). IFD results in increased hospital and ICU costs, with pharmacy costs, including antifungal treatment, being major determinants. Consumption of costly antifungal drugs may be a novel resource metric with wider generalizability than cost alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917 · cited 1×
“sion; IFD classification according to accepted criteria (10); and in-hospital mor-”
BackgroundSorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005) · Blood · doi:10.1182/blood-2005-05-2004 · Cited by 2,969
Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie, E. J., Walsh, T. J., Ito, J., Andes, D. R., Baddley, J. W., Brown, J. M., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651263 · Cited by 1,456
Neofytos, D., Horn, D., Anaissie, E., Steinbach, W., Olyaei, A., Fishman, J., Pfaller, M., Chang, C., Webster, K., & Marr, K. (2009) · Clinical Infectious Diseases · doi:10.1086/595846 · Cited by 801
Morgan, J., Meltzer, M. I., Plikaytis, B. D., Sofair, A. N., Huie-White, S., Wilcox, S., Harrison, L. H., Seaberg, E. C., Hajjeh, R. A., & Teutsch, S. M. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502581 · Cited by 437
The direct cost and incidence of systemic fungal infections
Wilson, L. S., Reyes, C. M., Stolpman, M., Speckman, J., Allen, K., & Beney, J. (2002) · Value in Health · doi:10.1046/j.1524-4733.2002.51108.x · Cited by 374
The Impact of Candidemia on Length of Hospital Stay, Outcome, and Overall Cost of Illness
Rentz, A. M., Halpern, M. T., & Bowden, R. (1998) · Clinical Infectious Diseases · doi:10.1086/514955 · Cited by 310 · cited 4×
“12 Antifungal drugs 26,219 4,775 21,444 (27) 0.”
BackgroundMethodResultInfluentialFactors associated with mortality in transplant patients with invasive aspergillosis
Baddley, J. W., Andes, D. R., Marr, K. A., Kontoyiannis, D. P., Alexander, B. D., Kauffman, C. A., Oster, R. A., Anaissie, E. J., Walsh, T. J., Schuster, M. G., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/652768 · Cited by 303 · cited 1×
“Improvement in the short-term survival of patients with invasive aspergillosis (IA) (22, 24) is encouraging, but crude mortality rates remain high at 30% in patients with acute myeloid leukemia (AML) (24) and 57% in hematopoietic stem cell (HSCT) recipients (1).”
BackgroundKim, A., Nicolau, D. P., & Kuti, J. L. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01903.x · Cited by 60
Chang, D. C., Burwell, L. A., Lyon, G. M., Pappas, P. G., Chiller, T. M., Wannemuehler, K. A., Fridkin, S. K., & Park, B. J. (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/524324 · Cited by 51 · cited 1×
“These studies (16, 20, 31), like others now 10 years old (8, 27, 28, 35), used administrative data sets, which have poor case detection (6); in our case, an administrative IFD diagnosis was absent for 13 possible case patients.”
Method
Cited by
Sanguinetti, M., & Posteraro, B. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.01640-16 · Cited by 154
“Invasive mold infections continue to occur among immunocompromised patients, particularly those receiving hematopoietic stem cell or solid-organ transplantation (1), and are associated with increased health care costs (2).”
BackgroundPagano, L., Busca, A., Candoni, A., Cattaneo, C., Cesaro, S., Fanci, R., Nadali, G., Potenza, L., Russo, D., Tumbarello, M., et al. (2017) · Blood Reviews · doi:10.1016/j.blre.2016.09.002 · Cited by 148
Pfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00840-19 · Cited by 80
Metadata
- Authors
- Ananda-Rajah, M. R., Cheng, A., Morrissey, C. O., Spelman, T., Dooley, M., Neville, A. M., & Slavin, M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-05
- Volume
- 55
- Issue
- 5
- Pages
- 1953-1960
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2125325650
- Cited by
- 84
- References
- 10
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Attributable Hospital Cost and Antifungal Treatment of Invasive Fungal Diseases in High-Risk Hematology Patients: an Economic Modeling Approach. https://app.cochat.ai/papers/10.1128/aac.01423-10
- The paper
- Ananda-Rajah, M. R., Cheng, A., Morrissey, C. O., Spelman, T., Dooley, M., Neville, A. M., & Slavin, M. (2011). Attributable Hospital Cost and Antifungal Treatment of Invasive Fungal Diseases in High-Risk Hematology Patients: an Economic Modeling Approach. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01423-10
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.